ArticleToxics2026
Tributyltin Alters Hepatic Immune Microenvironment to ProMote Liver Fibrosis Progression in Rats.
Article in Toxics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Tributyltin (TBT) is well known for inducing imposex in mollusks. Studies have shown its hepatotoxicity and immunotoxicity in laboratory animals, with macrophages playing a crucial role in maintaining hepatic homeostasis and influencing disease progression; however, no research has yet explored its effects on hepatotoxicity and immunotoxicity based on hepatic macrophages. To address this gap, weaned rats were treated with corn oil or TBT (0.5, 5, or 50 μg/kg) via oral gavage every three days for 60 days. Liver sections were then subjected to hematoxylin and eosin staining, Oil Red O staining, Sirius Red staining, immunohistochemistry, and immunofluorescence to assess the effects of TBT. Hepatic function and inflammatory state were evaluated by serum biochemistry and quantitative reverse transcription-PCR (qPCR), respectively. Histological examination indicated that TBT exposure did not increase hepatic lipid accumulation but resulted in hepatocyte edema and congestion in the 5 and 50 μg/kg groups, accompanied by progressive hepatic fibrosis. In parallel, 50 μg/kg TBT increased the number of macrophages, driven by an increase in the CD206
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.